Shonit Punwani

List of Publications by Year
in descending order

43 papers	3,930 citations	361045 20 h-index	301761 39 g-index
45 all docs	45 docs citations	45 times ranked	6005 citing authors

#	Article	IF	Citations
1	Inter-reader agreement of the PI-QUAL score for prostate MRI quality in the NeuroSAFE PROOF trial. European Radiology, 2022, 32, 879-889.	2.3	32
2	Prostate MRI quality: a critical review of the last 5 years and the role of the PI-QUAL score. British Journal of Radiology, 2022, 95, 20210415.	1.0	22
3	Diagnostic Accuracy of Abbreviated Bi-Parametric MRI (a-bpMRI) for Prostate Cancer Detection and Screening: A Multi-Reader Study. Diagnostics, 2022, 12, 231.	1.3	5
4	Histo-MRI map study protocol: a prospective cohort study mapping MRI to histology for biomarker validation and prediction of prostate cancer. BMJ Open, 2022, 12, e059847.	0.8	0
5	Differentiating False Positive Lesions from Clinically Significant Cancer and Normal Prostate Tissue Using VERDICT MRI and Other Diffusion Models. Diagnostics, 2022, 12, 1631.	1.3	0
6	Certification in reporting multiparametric magnetic resonance imaging of the prostate: recommendations of a UK consensus meeting. BJU International, 2021, 127, 304-306.	1.3	32
7	Synthesizing VERDICT Maps from Standard DWI Data Using GANs. Lecture Notes in Computer Science, 2021, , 58-67.	1.0	1
8	Evaluation of PSA and PSA Density in a Multiparametric Magnetic Resonance Imaging-Directed Diagnostic Pathway for Suspected Prostate Cancer: The INNOVATE Trial. Cancers, 2021, 13, 1985.	1.7	10
9	Standardisation of prostate multiparametric MRI across a hospital network: a London experience. Insights Into Imaging, 2021, 12, 52.	1.6	11
10	Understanding PI-QUAL for prostate MRI quality: a practical primer for radiologists. Insights Into Imaging, 2021, 12, 59.	1.6	43
11	Mapping PSA density to outcome of MRI-based active surveillance for prostate cancer through joint longitudinal-survival models. Prostate Cancer and Prostatic Diseases, 2021, 24, 1028-1031.	2.0	10
12	Emerging methods for prostate cancer imaging: evaluating cancer structure and metabolic alterations more clearly. Molecular Oncology, 2021, 15, 2565-2579.	2.1	5
13	Which Prostate Cancers are Undetected by Multiparametric Magnetic Resonance Imaging in Men with Previous Prostate Biopsy? An Analysis from the PICTURE Study. European Urology Open Science, 2021, 30, 16-24.	0.2	4
14	Computer-aided diagnosis of prostate cancer using multiparametric MRI and clinical features: A patient-level classification framework. Medical Image Analysis, 2021, 73, 102153.	7.0	19
15	Unsupervised Domain Adaptation with Semantic Consistency Across Heterogeneous Modalities for MRI Prostate Lesion Segmentation. Lecture Notes in Computer Science, 2021, , 90-100.	1.0	2
16	AutoProstate: Towards Automated Reporting of Prostate MRI for Prostate Cancer Assessment Using Deep Learning. Cancers, 2021, 13, 6138.	1.7	10
17	A Multicentre Analysis of the Detection of Clinically Significant Prostate Cancer Following Transperineal Image-fusion Targeted and Nontargeted Systematic Prostate Biopsy in Men at Risk. European Urology Oncology, 2020, 3, 262-269.	2.6	28
18	Added value of diffusion€weighted images and dynamic contrast enhancement in multiparametric magnetic resonance imaging for the detection of clinically significant prostate cancer in the PICTURE trial. BJU International, 2020, 125, 391-398.	1.3	8

#	Article	IF	Citations
19	The Role of Percentage of Prostate-specific Antigen Reduction After Focal Therapy Using High-intensity Focused Ultrasound for Primary Localised Prostate Cancer. Results from a Large Multi-institutional Series. European Urology, 2020, 78, 155-160.	0.9	18
20	Additional Value of Dynamic Contrast-enhanced Sequences in Multiparametric Prostate Magnetic Resonance Imaging: Data from the PROMIS Study. European Urology, 2020, 78, 503-511.	0.9	27
21	Harnessing Uncertainty in Domain Adaptation for MRI Prostate Lesion Segmentation. Lecture Notes in Computer Science, 2020, , 510-520.	1.0	17
22	Re: Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes?. Journal of Urology, 2020, 204, 1065-1066.	0.2	0
23	Machine learning classifiers can predict Gleason pattern 4 prostate cancer with greater accuracy than experienced radiologists. European Radiology, 2019, 29, 4754-4764.	2.3	55
24	Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed non-small-cell lung cancer: the prospective Streamline L trial. Lancet Respiratory Medicine,the, 2019, 7, 523-532.	5.2	50
25	Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed colorectal cancer: the prospective Streamline C trial. The Lancet Gastroenterology and Hepatology, 2019, 4, 529-537.	3.7	51
26	VERDICT MRI for Prostate Cancer: Intracellular Volume Fraction versus Apparent Diffusion Coefficient. Radiology, 2019, 291, 391-397.	3.6	52
27	VERDICT MRI validation in fresh and fixed prostate specimens using patientâ€specific moulds for histological and MR alignment. NMR in Biomedicine, 2019, 32, e4073.	1.6	22
28	Mediumâ€term oncological outcomes in a large cohort of men treated with either focal or hemiâ€ablation using highâ€intensity focused ultrasonography for primary localized prostate cancer. BJU International, 2019, 124, 431-440.	1.3	93
29	Localising occult prostate cancer metastasis with advanced imaging techniques (LOCATE trial): a prospective cohort, observational diagnostic accuracy trial investigating wholeâ€"body magnetic resonance imaging in radio-recurrent prostate cancer. BMC Medical Imaging, 2019, 19, 90.	1.4	9
30	Simplified Luminal Water Imaging for the Detection of Prostate Cancer From Multiecho T_2 MR Images. Journal of Magnetic Resonance Imaging, 2019, 50, 910-917.	1.9	16
31	VERDICTâ€AMICO: Ultrafast fitting algorithm for nonâ€invasive prostate microstructure characterization. NMR in Biomedicine, 2019, 32, e4019.	1.6	19
32	Multi-parametric MRI zone-specific diagnostic model performance compared with experienced radiologists for detection of prostate cancer. European Radiology, 2019, 29, 4150-4159.	2.3	8
33	Whole-body MRI compared with standard pathways for staging metastatic disease in lung and colorectal cancer: the Streamline diagnostic accuracy studies. Health Technology Assessment, 2019, 23, 1-270.	1.3	34
34	Characterizing indeterminate (Likert-score 3/5) peripheral zone prostate lesions with PSA density, PI-RADS scoring and qualitative descriptors on multiparametric MRI. British Journal of Radiology, 2018, 91, 20170645.	1.0	23
35	National implementation of multiâ€parametric magnetic resonance imaging for prostate cancer detection â€" recommendations from a <scp>UK</scp> consensus meeting. BJU International, 2018, 122, 13-25.	1.3	106
36	MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. New England Journal of Medicine, 2018, 378, 1767-1777.	13.9	2,036

#	Article	IF	Citations
37	Prostate cancer diagnostic pathway: Is a one-stop cognitive MRI targeted biopsy service a realistic goal in everyday practice? A pilot cohort in a tertiary referral centre in the UK. BMJ Open, 2018, 8, e024941.	0.8	14
38	Streamlining staging of lung and colorectal cancer with whole body MRI; study protocols for two multicentre, non-randomised, single-arm, prospective diagnostic accuracy studies (Streamline C and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 21		
39	Imaging biomarker roadmap for cancer studies. Nature Reviews Clinical Oncology, 2017, 14, 169-186.	12.5	792
40	INNOVATE: A prospective cohort study combining serum and urinary biomarkers with novel diffusion-weighted magnetic resonance imaging for the prediction and characterization of prostate cancer. BMC Cancer, 2016, 16, 816.	1.1	40
41	Visually directed vs. software-based targeted biopsy compared to transperineal template mapping biopsy in the detection of clinically significant prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 424.e9-424.e16.	0.8	44
42	Microstructural Characterization of Normal and Malignant Human Prostate Tissue With Vascular, Extracellular, and Restricted Diffusion for Cytometry in Tumours Magnetic Resonance Imaging. Investigative Radiology, 2015, 50, 218-227.	3.5	137
43	Whole Body (WB) MRI in Newly Diagnosed Multiple Myeloma (MM): Fat Fraction Changes at 8 Weeks Predict Response to Induction with Bortezomib Regimens. Blood, 2015, 126, 1850-1850.	0.6	1